Continuing Dr. West's theme discussing new therapies for patients with acquired resistance, I'd like to answer a few questions about HSP 90 inhibitors that have caught my attention on GRACE over the past few weeks, and in particular, highlight my "pet" targeted agent, AUY922. HSP 90 inhibitors are drugs that many of you already know about-they are being studied in patients with ALK(+)lung cancer and as a 2nd line therapy option for all patients with lung cancer with Taxotere.
Copyright © 2021 Global Resource for Advancing Cancer Education
Site by Freelock
Comments
test test test
test
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nullam id sapien quis lorem sollicitudin